Biogen Stock Chart Fibonacci Analysis 081325Trading Idea
1) Find a FIBO slingshot
2) Check FIBO 61.80% level
3) Entry Point > 134/61.80%
Chart time frame:B
A) 15 min(1W-3M)
B) 1 hr(3M-6M)
C) 4 hr(6M-1year)
D) 1 day(1-3years)
Stock progress:A
A) Keep rising over 61.80% resistance
B) 61.80% resistance
C) 61.80% support
D) Hit the bottom
E)
Key facts today
Biogen's shares fell 3% after Needham analyst Ami Fadia maintained a 'Hold' rating and unchanged price target, disappointing investors who expected a more positive outlook.
850 ARS
1.49 T ARS
8.49 T ARS
About Biogen Inc.
Sector
Industry
CEO
Christopher A. Viehbacher
Website
Headquarters
Cambridge
Founded
1978
ISIN
ARBCOM4601A8
FIGI
BBG00PCCBPX0
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Related stocks
BIIB Bounces from VWAP ClusterBIIB is climbing after bouncing off a VWAP cluster (yellow and green zones) and reclaiming key levels. Price held support near $125 and is now pushing toward the upper range near $134.
Volume is slightly above average (1.23M vs. 1.21M MA), and price structure looks constructive with a clean higher
BIIB - Picture Perfect Market Maker ModelQuite Frankly This Is a Piece of Art.
Ai is been helping Bio Tech massively
Using the 3 Month and 1 Month Time frames we have a perfect Market maker model. Consolidation up top with market manipulation straight to distribution (A,M,D)
- 2 main accumulations before it hit's a perfect fair value g
BIIB Long, Coming Soon!The price has sold off from the $207.59 pivot level, dropping to $193.84 as of the Monday, September 30th close. The sharp decline from $200 to $190 over two days last week was largely due to sector-wide weakness, as reflected in the IBB (Biotech ETF). Since then, both the ETF and BIIB have been con
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
BIIB6071255
Biogen Inc. 6.45% 15-MAY-2055Yield to maturity
—
Maturity date
May 15, 2055
BIIB6071254
Biogen Inc. 5.05% 15-JAN-2031Yield to maturity
—
Maturity date
Jan 15, 2031
BIIB5133379
Biogen Inc. 3.25% 15-FEB-2051Yield to maturity
—
Maturity date
Feb 15, 2051
BIIB5133378
Biogen Inc. 3.25% 15-FEB-2051Yield to maturity
—
Maturity date
Feb 15, 2051
BIIB6071069
Biogen Inc. 5.75% 15-MAY-2035Yield to maturity
—
Maturity date
May 15, 2035
BIIB4981508
Biogen Inc. 3.15% 01-MAY-2050Yield to maturity
—
Maturity date
May 1, 2050
BIIB4981506
Biogen Inc. 2.25% 01-MAY-2030Yield to maturity
—
Maturity date
May 1, 2030
US9062XAD5
Biogen Inc. 5.2% 15-SEP-2045Yield to maturity
—
Maturity date
Sep 15, 2045
See all BIIB bonds
Curated watchlists where BIIB is featured.